Novel approaches to the management of noneosinophilic asthma

Therapeutic Advances in Respiratory Disease

Volumn 10, Issue 3, 2016, Pages 211-234

  Thomson, Neil C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

airway inflammation; asthma; biological agents; biomarkers; cigarette smoking; corticosteroid insensitivity; eosinophils; neutrophils; small molecules

Indexed keywords

6 [3 (DIMETHYLCARBAMOYL)PHENYLSULFONYL] 4 (3 METHOXYANILINO) 8 METHYL 3 QUINOLINECARBOXAMIDE; AQX 1125; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN INHIBITOR; ATORVASTATIN; AZD 7624; AZITHROMYCIN; BECLOMETASONE; BIOLOGICAL MARKER; CANAKINUMAB; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; COLECALCIFEROL; CORTICOSTEROID; FLUTICASONE PROPIONATE; GSK 2269557; IMATINIB; LOSMAPIMOD; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; ROFLUMILAST; RPL 554; THEOPHYLLINE; TOCILIZUMAB; UNCLASSIFIED DRUG; ANTIASTHMATIC AGENT; BIOLOGICAL FACTOR; GLUCOCORTICOID;

AIRWAY OBSTRUCTION; ASTHMA; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL COUNT; HUMAN; LEUKOCYTE ACTIVATION; LOW DRUG DOSE; MOLECULAR PATHOLOGY; NEUTROPHIL COUNT; NEUTROPHILIC AIRWAY INFLAMMATION; NONEOSINOPHILIC ASTHMA; NONHUMAN; OCCUPATIONAL EXPOSURE; OFF LABEL DRUG USE; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFLAMMATION; REVIEW; SMOKING CESSATION; SPUTUM LEVEL; SYMPTOM; TH2 CELL; ANIMAL; EOSINOPHIL; INFLAMMATION; METABOLISM; NEUTROPHIL; PATHOPHYSIOLOGY; PROCEDURES;

ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; BIOLOGICAL FACTORS; EOSINOPHILS; GLUCOCORTICOIDS; HUMANS; INFLAMMATION; NEUTROPHILS; SMOKING CESSATION;

EID: 84973551910     PISSN: 17534658     EISSN: 17534666     Source Type: Journal    
DOI: 10.1177/1753465816632638     Document Type: Review

References (207)

1. Agustí A., Antó J., Auffray C., Barbé F., Barreiro E., Dorca J., et al. (2015) Personalized respiratory medicine: exploring the horizon, addressing the issues. Summary of a BRN-AJRCCM Workshop Held in Barcelona on June 12, 2014. Am J Resp Crit Care Med 191: 391-401.
2. Al-Samri M., Benedetti A., Préfontaine D., Olivenstein R., Lemière C., Nair P., et al. (2010) Variability of sputum inflammatory cells in asthmatic patients receiving corticosteroid therapy: a prospective study using multiple samples. J Allergy Clin Immunol 125: 1161-1163.
3. Anees W., Huggins V., Pavord I., Robertson A., Burge P., (2002) Occupational asthma due to low molecular weight agents: eosinophilic and noneosinophilic variants. Thorax 57: 231-236.
4. Arron J., Choy D., Laviolette M., Kelsen S., Hatab A., Leigh R., et al. (2014) Disconnect between sputum neutrophils and other measures of airway inflammation in asthma. Eur Respir J 43: 627-629.
5. Arron J., Scheerens H., Matthews J., David R., (2013) Redefining approaches to asthma: developing targeted biologic therapies. Adv Pharmacol-Immunopharmacol 66: 1-49.
6. Bacci E., Cianchetti S., Bartoli M., Dente F., Di Franco A., Vagaggini B., et al. (2006) Low sputum eosinophils predict the lack of response to beclomethasone in symptomatic asthmatic patients. Chest 129: 565-572.
7. Bacci E., Latorre M., Cianchetti S., Bartoli M., Costa F., Di Franco A., et al. (2012) Transient sputum eosinophilia may occur over time in noneosinophilic asthma and this is not prevented by salmeterol. Respirology 17: 1199-1206.
8. Bain G., King C., Schaab K., Rewolinski M., Norris V., Ambery C., et al. (2013) Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor. Br J Clin Pharmacol 75: 779-790.
9. Baines K., Simpson J., Bowden N., Scott R., Gibson P., (2010) Differential gene expression and cytokine production from neutrophils in asthma phenotypes. Eur Respir J 35: 522-531.
10. Baines K., Simpson J., Wood L., Scott R., Fibbens N., Powell H., et al. (2014) Sputum gene expression signature of 6 biomarkers discriminates asthma inflammatory phenotypes. J Allergy Clin Immunol 133: 997-1007.
11. Baines K., Simpson J., Wood L., Scott R., Gibson P., (2011) Systemic upregulation of neutrophil alpha-defensins and serine proteases in neutrophilic asthma. Thorax 66: 942-947.
12. Balloy V., Deveaux A., Lebeaux D., Tabary O., Le Rouzic P., Ghigo J., et al. (2014) Azithromycin analogue CSY0073 attenuates lung inflammation induced by LPS challenge. Br J Pharmacol 171: 1783-1794.
13. Barnes P., (2009) Role of HDAC2 in the pathophysiology of COPD. Annu Rev Physiol 71: 451-464.
14. Bateman E., Izquierdo J., Harnest U., Hofbauer P., Magyar P., Schmid-Wirlitsch C., et al. (2006) Efficacy and safety of roflumilast in the treatment of asthma. Ann Allergy Asthma Immunol 96: 679-686.
15. Bauer C., Zavitz C., Botelho F., Lambert K., Brown E., Mossman K., et al. (2010) Treating viral exacerbations of chronic obstructive pulmonary disease: insights from a mouse model of cigarette smoke and H1N1 influenza infection. PLoS ONE 5: e13251.
16. Bel E., Wenzel S., Thompson P., Prazma C., Keene O., Yancey S., et al. (2014) Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Eng J Med 371: 1189-1197.
17. Belvisi M., Hele D., (2008) Peroxisome proliferator-activated receptors as novel targets in lung disease. Chest 134: 152-157.
18. Berlin A., Lukacs N., (2005) Treatment of cockroach allergen asthma model with imatinib attenuates airway responses. Am J Respir Crit Care Med 171: 35-39.
19. Berry M., Hargadon B., Shelley M., Parker D., Shaw D., Green R., et al. (2006) Inhibition of tumor necrosis factor α for refractory asthma. N Eng J Med 354: 754-758.
20. Berry M., Morgan A., Shaw D., Parker D., Green R., Brightling C., et al. (2007) Pathological features and inhaled corticosteroid response of eosinophilic and noneosinophilic asthma. Thorax 62: 1043-1049.
21. Bhavsar P., Khorasani N., Hew M., Johnson M., Chung K., (2010) Effect of P38 Mapk inhibition on corticosteroid suppression of cytokine release in severe asthma. Eur Respir J 35: 750-756.
22. Boulet L., Lemiere C., Archambault F., Carrier G., Descary M., Deschesnes F., (2006) Smoking and asthma: clinical and radiologic features, lung function, and airway inflammation. Chest 129: 661-668.
23. Bourke J., Bai Y., Donovan C., Esposito J., Tan X., Sanderson M., (2014) Novel small airway bronchodilator responses to rosiglitazone in mouse lung slices. Am J Respir Cell Mol Biol 50: 748-756.
24. Bousquet J., Aubier M., Sastre J., Izquierdo J., Adler L., Hofbauer P., et al. (2006) Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy 61: 72-78.
25. Braganza G., Chaudhuri R., Mcsharry C., Weir C., Donnelly I., Jolly L., et al. (2011) Effects of short-term treatment with atorvastatin in smokers with asthma-a randomized controlled trial. BMC Pulm Med 11: 16.
26. Brooks C., Gibson P., Douwes J., Van Dalen C., Simpson J., (2013) Relationship between airway neutrophilia and ageing in asthmatics and non-asthmatics. Respirology 18: 857-865.
27. Brooks C., Van Dalen C., Zacharasiewicz A., Simpson J., Harper J., Le Gros G., et al. (2016) Absence of airway inflammation in a large proportion of adolescents with asthma. Respirology 22. doi: 10.1111/resp.12701. [Epub ahead of print].
28. Brusselle G., Vanderstichele C., Jordens P., Deman R., Slabbynck H., Ringoet V., et al. (2013) Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax 68: 322-329.
29. Busse W., Holgate S., Kerwin E., Chon Y., Feng J., Lin J., et al. (2013) Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-L-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 188: 1294-1302.
30. Cameron E., Chaudhuri R., Mair F., Mcsharry C., Greenlaw N., Weir C., et al. (2013) Randomised controlled trial of azithromycin in smokers with asthma. Eur Respir J 42: 1412-1415.
31. Cameron E., Mcsharry C., Chaudhuri R., Farrow S., Thomson N., (2012) Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments. Clin Exp Allergy 42: 1302-1312.
32. Campbell L., Maxwell P., Waugh D., (2013) Rationale and means to target pro-inflammatory interleukin-8 (CXCL8) signaling in cancer. Pharmaceuticals 6: 929-959.
33. Castro M., King T., Kunselman S., Hünnemeyer A., Lahu G., Templin S., et al. (2014) Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. JAMA 311 (20): 2083-2091.
34. Chalmers G., Macleod K., Little S., Thomson L., Mcsharry C., Thomson N., (2002) Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 57: 226-230.
35. Chapman R., House A., Richard J., Prelusky D., Lamca J., Wang P., et al. (2010) Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration. Eur J Pharmacol 643: 274-281.
36. Chapman R., Phillips J., Hipkin R., Curran A., Lundell D., Fine J., (2009) CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 121: 55-68.
37. Chaudhuri R., Livingston E., Mcmahon A., Lafferty J., Fraser I., Spears M., et al. (2006) Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med 174: 127-133.
38. Chaudhuri R., Norris V., Kelly K., Zhu C., Ambery C., Lafferty J., et al. (2014) Effects of a flap inhibitor, GSK2190915, in asthmatics with high sputum neutrophils. Pulm Pharmacol Ther 27: 62-69.
39. Chesné J., Braza F., Mahay G., Brouard S., Aronica M., Magnan A., (2014) IL-17 in severe asthma. Where do we stand? Am J Respir Crit Care Med 190: 1094-1101.
40. Choy D., Hart K., Borthwick L., Shikotra A., Nagarkar D., Siddiqui S., et al. (2015) Th2 and Th17 inflammatory pathways are reciprocally regulated in asthma. Sci Transl Med 7: 301ra129-301ra129.
41. Chung K., (2011) P38 mitogen-activated protein kinase pathways in asthma and COPD. Chest 139: 1470-1479.
42. Cohen S., Fleischmann R., (2010) Kinase inhibitors: a new approach to rheumatoid arthritis treatment. Curr Opin Rheumatol 22: 330-335
43. Corren J., Lemanske R., Hanania N., Korenblat P., Parsey M., Arron J., et al. (2011) Lebrikizumab treatment in adults with asthma. N Eng J Med 365: 1088-1098.
44. Cowan D., Cowan J., Palmay R., Williamson A., Taylor D., (2010) Effects of steroid therapy on inflammatory cell subtypes in asthma. Thorax 65: 384-390.
45. Cox G., (1995) Glucocorticoid treatment inhibits apoptosis in human neutrophils. separation of survival and activation outcomes. J Immunol 154: 4719-4725.
46. Culic O., Erakovic V., Parnham M., (2001) Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 429: 209-229.
47. D'Silva L., Cook R., Allen C., Hargreave F., Parameswaran K., (2007) Changing pattern of sputum cell counts during successive exacerbations of airway disease. Respir Med 101: 2217-2220.
48. Dave S., Brian R., Malcom B., Marie A., Sara C., Fabrizia M., et al. (2014) The effect of the inhaled PDE4 inhibitor CHF6001 on allergen-induced inflammation in asthmatic subjects. Am J Resp Crit Care Med: A4175-A4175.
49. Davis B., Zeki A., Bratt J., Wang L., Filosto S., Walby W., et al. (2013) Simvastatin inhibits smoke-induced airway epithelial injury: implications for COPD therapy. Eur Respir J 42: 350-361.
50. De Groot J., Van Roon E., Storm H., Veeger N., Zwinderman A., Hiemstra P., et al. (2015) Vitamin D reduces eosinophilic airway inflammation in nonatopic asthma. J Allergy Clin Immunol 135: 670-675.
51. De Savi C., Cox R., Warner D., Cook A., Dickinson M., Mcdonough A., et al. (2014) Efficacious inhaled PDE4 inhibitors with low emetic potential and long duration of action for the treatment of COPD. J Med Chem 57: 4661-4676.
52. De Soyza A., Pavord I., Elborn J., Smith D., Wray H., Puu M., et al. (2015) A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis. Eur Respir J 46: 1021-1032.
53. Dejager L., Dendoncker K., Eggermont M., Souffriau J., Van Hauwermeiren F., Willart M., et al. (2015) Neutralizing TNF[alpha] restores glucocorticoid sensitivity in a mouse model of neutrophilic airway inflammation. Mucosal Immunol 8: 1212-1225.
54. Denlinger L., King T., Cardet J., Craig T., Holguin F., Jackson D., et al. (2015) Vitamin D supplementation and the risk of colds in patients with asthma. Am J Resp Crit Care Med 5. [Epub ahead of print].
55. Desai D., Newby C., Symon F., Haldar P., Shah S., Gupta S., et al. (2013) Elevated sputum interleukin-5 and submucosal eosinophilia in obese individuals with severe asthma. Am J Respir Crit Care Med 188: 657-663.
56. Dixon A., Subramanian M., Desarno M., Black K., Lane L., Holguin F., (2015) A pilot randomized controlled trial of pioglitazone for the treatment of poorly controlled asthma in obesity. Respir Res 16: 143.
57. Donovan C., Bailey S., Tran J., Haitsma G., Ibrahim Z., Foster S., et al. (2015) Rosiglitazone elicits in vitro relaxation in airways and precision cut lung slices from a mouse model of chronic allergic airways disease. Am J Physiol Lung Cell Mol Physiol 309: L1219-1228.
58. Dougherty R., Sidhu S., Raman K., Solon M., Solberg O., Caughey G., et al. (2010) Accumulation of intraepithelial mast cells with a unique protease phenotype in Th2-high asthma. J Allergy Clin Immunol 125: 1046-1053.
59. Doukas J., Eide L., Stebbins K., Racanelli-Layton A., Dellamary L., Martin M., et al. (2009) Aerosolized phosphoinositide 3-kinase {gamma}/{delta} inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther 328: 758-765.
60. Essilfie A., Horvat J., Kim R., Mayall J., Pinkerton J., Beckett E., et al. (2015) Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. Thorax 70: 458-467.
61. Evans J., Ferguson A., Mosley R., Hutchinson J., (2008) What's all the flap about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases. Trends Pharmacol Sc 29: 72-78.
62. Fahy J., Kim K., Liu J., Boushey H., (1995) Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol 95: 843-852.
63. Franciosi L., Diamant Z., Banner K., Zuiker R., Morelli N., Kamerling I., et al. (2013) Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med 1: 714-727.
64. Fu J., Baines K., Wood L., Gibson P., (2013) Systemic inflammation is associated with differential gene expression and airway neutrophilia in asthma. OMICS 17: 187-199.
65. Fujitani Y., Trifilieff A., (2003) In vivo and in vitro effects of SAR 943, a rapamycin analogue, on airway inflammation and remodeling. Am J Respir Crit Care Med 167: 193-198.
66. Furukawa T., Sakagami T., Koya T., Hasegawa T., Kawakami H., Kimura Y., et al. (2015) Characteristics of eosinophilic and noneosinophilic asthma during treatment with inhaled corticosteroids. J Asthma 52: 417-422.
67. Futosi K., Fodor S., Mócsai A., (2013) Neutrophil cell surface receptors and their intracellular signal transduction pathways. Internat Immunopharmacol 17: 1185-1197.
68. Gaga M., Brand P., Thomson N., (2015) The quest for the grail: multidimensional efforts for understanding and targeting severe asthma. Eur Respir J 46: 1227-1231.
69. Gao P., Gibson P., Baines K., Yang I., Upham J., Reynolds P., et al. (2015) Anti-inflammatory deficiencies in neutrophilic asthma: reduced galectin-3 and IL-1RA/IL-1β. Respir Res 16: 5.
70. Gauvreau G., Boulet L., Schmid-Wirlitsch C., Cote J., Duong M., Killian K., et al. (2011) Roflumilast attenuates allergen-induced inflammation in mild asthmatic subjects. Respir Res 12: 140.
71. Gibson P., Simpson J., Saltos N., (2001) Heterogeneity of airway inflammation in persistent asthma: evidence of neutrophilic inflammation and increased sputum interleukin-8. Chest 119: 1329-1336.
72. Gielen V., Johnston S., Edwards M., (2010) Azithromycin induces anti-viral responses in bronchial epithelial cells. Eur Respir J 36: 646-654.
73. Godon P., Boulet L., Malo J., Cartier A., Lemière C., (2002) Assessment and evaluation of symptomatic steroid-naive asthmatics without sputum eosinophilia and their response to inhaled corticosteroids. Eur Respir J 20: 1364-1369.
74. Green B., Wiriyachaiporn S., Grainge C., Rogers G., Kehagia V., Lau L., et al. (2014) Potentially pathogenic airway bacteria and neutrophilic inflammation in treatment resistant severe asthma. PLoS ONE 9: e100645.
75. Green R., Brightling C., Mckenna S., Hargadon B., Parker D., Bradding P., et al. (2002a) Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 360: 1715-1721.
76. Green R., Brightling C., Woltmann G., Parker D., Wardlaw A., Pavord I., (2002b) Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax 57: 875-879.
77. Greenwood J., Steinman L., Zamvil S., (2006) Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 6: 358-370.
78. Guntur V., Reinero C., (2012) The potential use of tyrosine kinase inhibitors in severe asthma. Curr Opin Allergy Clin Immunol 12: 68-75.
79. Haldar P., Pavord I., (2007) Noneosinophilic asthma: a distinct clinical and pathologic phenotype. J Allergy Clin Immunol 119: 1043-1052.
80. Haldar P., Pavord I., Shaw D., Berry M., Thomas M., Brightling C., et al. (2008) Cluster analysis and clinical asthma phenotypes. Am J Resp Crit Car Med 178: 218-224.
81. Hammaker D., Firestein G., (2010) Go upstream, young man: lessons learned from the P38 saga. Ann Rheum Dis 69, Suppl 1.
82. Hancox R., Cowan D., Aldridge R., Cowan J., Palmay R., Williamson A., et al. (2012) Asthma phenotypes: consistency of classification using induced sputum. Respirology 17: 461-466.
83. Hao M., Lin J., Shu J., Zhang X., Luo Q., Pan L., et al. (2015) Clarithromycin might attenuate the airway inflammation of smoke-exposed asthmatic mice via affecting HDAC2. J Thorac Dis 7: 1189-1197.
84. Hastie A., Moore W., Li H., Rector B., Ortega V., Pascual R., et al. (2013) Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol 132: 72-80.
85. Hastie A., Moore W., Meyers D., Vestal P., Li H., Peters S., et al. (2010) Analyses of asthma severity phenotypes and inflammatory proteins in subjects stratified by sputum granulocytes. J Allergy Clin Immunol 125: 1028-1036.
86. Heaney L., Djukanovic R., Woodcock A., Walker S., Matthews J., Pavord I., et al. (2015) Research in progress: Medical Research Council United Kingdom Refractory Asthma Stratification Programme (RASP-UK). Thorax doi: 10.1136/thoraxjnl-2015-207326. [Epub ahead of print]
87. Hernandez M., Mills K., Almond M., Todoric K., Aleman M., Zhang H., et al. (2015) IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers. J Allergy Clin Immunol 135: 379-385.
88. Holgate S., Noonan M., Chanez P., Busse W., Dupont L., Pavord I., et al. (2011) Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J 37: 1352-1359.
89. Holz O., Khalilieh S., Ludwig-Sengpiel A., Watz H., Stryszak P., Soni P., et al. (2010) SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 35: 564-570.
90. Hothersall E., Mcsharry C., Thomson N., (2006) Potential therapeutic role for statins in respiratory disease. Thorax 61: 729-734.
91. Howarth P., Babu K., Arshad H., Lau L., Buckley M., Mcconnell W., et al. (2005) Tumour necrosis factor (TNF{Alpha}) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 60: 1012-1018.
92. Humbert M., De Blay F., Garcia G., Prud'homme A., Leroyer C., Magnan A., et al. (2009) Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy 64: 1194-1201.
93. Ito K., Caramori G., Adcock I.M., (2007) Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. J Pharmacol Exp Ther 321: 1-8.
94. Jatakanon A., Lim S., Pj B., (2000) Changes in sputum eosinophils predict loss of asthma control. Am J Repir Crit Care Med 161: 64-72.
95. Jayaram L., Pizzichini M., Cook R., Boulet L., Lemiere C., Pizzichini E., et al. (2006) Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 27: 483-494.
96. Katz L., Gleich G., Hartley B., Yancey S., Ortega H., (2014) Blood eosinophil count is a useful biomarker to identify patients with severe eosinophilic asthma. Annals Am Thor Soc 11: 531-536.
97. Kent S., Boyce M., Diamant Z., Singh D., O'Connor B., Saggu P., et al. (2013) The 5-lipoxygenase-activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma. Clin Exp Allergy 43: 177-186.
98. Khorasani N., Baker J., Johnson M., Chung K., Bhavsar P., (2015) Reversal of corticosteroid insensitivity by P38 MAPK inhibition in peripheral blood mononuclear cells from COPD. Int J Chron Obstruct Pulmon Dis 10: 283-291.
99. Kim R., Pinkerton J., Gibson P., Cooper M., Horvat J., Hansbro P., (2015a) Inflammasomes in COPD and neutrophilic asthma. Thorax 70: 1199-1201.
100. Kim S., Kim J., Park C., Kim T., Lee S., Kim Y., et al. (2015b) Effect of roflumilast on airway remodeling in a murine model of chronic asthma. Clin Exp Allergy doi: 10.1111/cea.12670. [Epub ahead of print].
101. Kirsten A., Förster K., Radeczky E., Linnhoff A., Balint B., Watz H., et al. (2015) The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD. Pulm Pharm Therap 31: 36-41.
102. Kobayashi Y., Wada H., Rossios C., Takagi D., Charron C., Barnes P., et al. (2013a) A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br J Pharmacol 169: 1024-1034.
103. Kobayashi Y., Wada H., Rossios C., Takagi D., Higaki M., Mikura S., et al. (2013b) A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-κB inhibition. J Pharmacol Exp Ther 345: 76-84.
104. Kupczyk M., Dahlén B., Sterk P., Nizankowska-Mogilnicka E., Papi A., Bel E., et al. (2014a) Stability of phenotypes defined by physiological variables and biomarkers in adults with asthma. Allergy 69: 1198-1204.
105. Kupczyk M., Ten Brinke A., Sterk P., Bel E., Papi A., Chanez P., et al. (2014b) Frequent exacerbators-a distinct phenotype of severe asthma. Clin Exp Allergy 44: 212-221.
106. Lakshmi S., Reddy A., Zhang Y., Sciurba F., Mallampalli R., Duncan S., et al. (2014) Down-regulated peroxisome proliferator-activated receptor γ (PPARγ) in lung epithelial cells promotes a pparγ agonist-reversible proinflammatory phenotype in chronic obstructive pulmonary disease (COPD). J Biol Chem 289: 6383-6393.
107. Lamblin C., Gosset P., Tillie-Leblond I., Saulnier F., Marquette C., Wallaert B., et al. (1998) Bronchial neutrophilia in patients with noninfectious status asthmaticus. Am J Respir Crit Care Med 157: 394-402.
108. Lazaar A., Sweeney L., Macdonald A., Alexis N., Chen C., Tal-Singer R., (2011) SB-656933, a novel CXCR2 selective antagonist, inhibits ex vivo neutrophil activation and ozone-induced airway inflammation in humans. Br J Clin Pharmacol 72: 282-293.
109. Lea S., Plumb J., Metcalfe H., Spicer D., Woodman P., Fox J., et al. (2014) The effect of peroxisome proliferator-activated receptor-γ ligands on in vitro and in vivo models of COPD. Eur Respir J 43: 409-420.
110. Leaker B., Barnes P., O'Connor B., (2013) Inhibition of LPS-induced airway neutrophilic inflammation in healthy volunteers with an oral CXCR2 antagonist. Respir Res 14: 137.
111. Leaker B., Barnes P., O'Connor B., Ali F., Tam P., Neville J., et al. (2014) The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma. Clin Exp Allergy 44: 1146-1153.
112. Lee K., Jeong J., Kim S., Cho S., Kolliputi N., Ko Y., et al. (2016) Phosphoinositide 3-kinase-δ regulates fungus-induced allergic lung inflammation through endoplasmic reticulum stress. Thorax 71: 52-63.
113. Lee J., Lee D., Kim E., Choe K., Oh Y., Shim T., et al. (2005) Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med 172: 987-993.
114. Lemière C., Boulet L., Chaboillez S., Forget A., Chiry S., Villeneuve H., et al. (2013) Work-exacerbated asthma and occupational asthma: do they really differ? J Allergy Clin Immunol 131: 704-710.
115. Lemiere C., Chaboillez S., Bohadana A., Blais L., Maghni K., (2014) Noneosinophilic responders with occupational asthma: a phenotype associated with a poor asthma prognosis. J Allergy Clin Immunol 133: 883-885.
116. Lemière C., Tremblay C., Fitzgerald M., Aaron S., Leigh R., Boulet L., et al. (2011) Effects of a short course of inhaled corticosteroids in noneosinophilic asthmatic subjects. Can Respir J 18: 278-282.
117. Leuppi J., Salome C., Jenkins C., Anderson S., Xuan W., Marks G., et al. (2001) Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med 163: 406-412.
118. Lipworth B., (2005) Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet 365: 167-175.
119. Little S., Chalmers G., Macleod K., Mcsharry C., Thomson N., (2000) Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma. Thorax 53: 232-234.
120. Little S., Macleod K., Chalmers G., Love J., Mcsharry C., Thomson N.C., (2002) Association of forced expiratory volume with disease duration and sputum neutrophils in chronic asthma. Am J Med 112: 446-452.
121. Maghni K., Lemiere C., Ghezzo H., Yuquan W., Malo J., (2004) Airway inflammation after cessation of exposure to agents causing occupational asthma. Am J Respir Crit Care Med 169: 367-372.
122. Maneechotesuwan K., Ekjiratrakul W., Kasetsinsombat K., Wongkajornsilp A., Barnes P., (2010) Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. J Allergy Clin Immunol 126: 754-762.
123. Maneechotesuwan K., Essilfie-Quaye S., Kharitonov S., Adcock I., Barnes P., (2007) Loss of control of asthma following inhaled corticosteroid withdrawal is associated with increased sputum interleukin-8 and neutrophils. Chest 132: 98-105.
124. Maneechotesuwan K., Kasetsinsombat K., Wongkajornsilp A., Barnes P., (2013) Decreased indoleamine 2,3-dioxygenase activity and IL-10/IL-17a ratio in patients with COPD. Thorax 68: 330-337.
125. Manni M., Trudeau J., Scheller E., Mandalapu S., Elloso M., Kolls J., et al. (2014) The complex relationship between inflammation and lung function in severe asthma. Mucosal Immunol 7: 1186-1198.
126. Marks-Konczalik J., Costa M., Robertson J., McKie E., Yang S., Pascoe S., (2015) A post-hoc subgroup analysis of data from a six month clinical trial comparing the efficacy and safety of losmapimod in moderate-severe copd patients with 1/22% and >2% blood eosinophils. Respir Med 109: 860-869.
127. Martineau A., Hanifa Y., Witt K., Barnes N., Hooper R., Patel M., et al. (2015) Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (Vidiflu). Thorax 70: 953-960.
128. Marwick J., Caramori G., Casolari P., Mazzoni F., Kirkham P., Adcock I., et al. (2010) A Role for phosphoinositol 3-kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 125: 1146-1153.
129. Marwick J., Caramori G., Stevenson C., Casolari P., Jazrawi E., Barnes P., et al. (2009) Inhibition of Pi3kdelta restores glucocorticoid function in smoking-induced airway inflammation in mice. Am J Respir Crit Care Med 179: 542-548.
130. McGrath K., Icitovic N., Boushey H., Lazarus S., Sutherland E., Chinchilli V., et al. (2012) A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med 185: 612-619.
131. McKay A., Leung B., Mcinnes I., Thomson N., Liew F., (2004) A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 172: 2903-2908.
132. Mercado N., Hakim A., Kobayashi Y., Meah S., Usmani O., Chung K., et al. (2012) Restoration of corticosteroid sensitivity by P38 mitogen activated protein kinase inhibition in peripheral blood mononuclear cells from severe asthma. PLoS ONE 7: e41582.
133. Miossec P., Kolls J., (2012) Targeting Il-17 and Th17 cells in chronic inflammation. Nat Rev Drug Discov 11: 763-776.
134. Moore W., Hastie A., Li X., Li H., Busse W., Jarjour N., et al. (2014) Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. J Allergy Clin Immunol 133: 1557-1563.
135. Moretto N., Caruso P., Bosco R., Marchini G., Pastore F., Armani E., et al. (2015) Chf6001, a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration. J Pharmacol Exp Ther 352: 559-567.
136. Morissette M., Shen P., Thayaparan D., Stämpfli M., (2015) Impacts of peroxisome proliferator-activated receptor-γ activation on cigarette smoke-induced exacerbated response to bacteria. Eur Respir J 45: 191-200.
137. Nair P., Aziz-Ur-Rehman A., Radford K., (2015) Therapeutic implications of 'neutrophilic asthma'. Curr Opin Pulm Med 21: 33-38
138. Nair P., Gaga M., Zervas E., Alagha K., Hargreave F., O'Byrne P., et al. (2012) Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy 42: 1097-1103.
139. Nanzer A., Chambers E., Ryanna K., Richards D., Black C., Timms P., et al. (2013) Enhanced production of IL-17a in patients with severe asthma is inhibited by 1î±25-dihydroxyvitamin D3 in a glucocorticoid-independent fashion. J Allergy Clin Immunol 132: 297-304.
140. Newby C., Agbetile J., Hargadon B., Monteiro W., Green R., Pavord I., et al. (2014) Lung function decline and variable airway inflammatory pattern: longitudinal analysis of severe asthma. J Allergy Clin Immunol 134: 287-294.
141. Newcomb D., Peebles R. Jr, (2013) Th17-mediated inflammation in asthma. Curr Opinion Immunol 25: 755-760.
142. Nials A., Tralau-Stewart C., Gascoigne M., Ball D., Ranshaw L., Knowles R., (2011) In vivo characterization of GSK256066, a high-affinity inhaled phosphodiesterase 4 inhibitor. J Pharmacol Exp Ther 337: 137-144.
143. O'Byrne P., Metev H., Puu M., Richter K., Keen C., (2015) Efficacy and safety of a CXCR2 antagonist, AZD5069, in severe, uncontrolled persistent asthma. Am J Resp Crit Care Med 256: A2503-A2503.
144. Ortega H., Liu M., Pavord I., Brusselle G., Fitzgerald J., Chetta A., et al. (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Eng J Med 371: 1198-1207.
145. Page C., Spina D., (2012) Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol 12: 275-286.
146. Pavord I., Brightling C., Woltmann G., Wardlaw A., (1999) Noneosinophilic corticosteroid unresponsive asthma. Lancet 353: 2213-2214.
147. Pavord I., Korn S., Howarth P., Bleecker E., Buhl R., Keene O., et al. (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380: 651-659.
148. Peters M., Mekonnen Z., Yuan S., Bhakta N., Woodruff P., Fahy J., (2014) Measures of gene expression in sputum cells can identify Th2-high and Th2-low subtypes of asthma. J Allergy Clin Immunol 133: 388-394.
149. Raundhal M., Morse C., Khare A., Oriss T., Milosevic J., Trudeau J., et al. (2015) High IFN-γ and low SLPI mark severe asthma in mice and humans. J Clin Invest 125: 3037-3050.
150. Reiter J., Demirel N., Mendy A., Gasana J., Vieira E., Colin A., et al. (2013) Macrolides for the long-term management of asthma-a meta-analysis of randomized clinical trials. Allergy 68: 1040-1049.
151. Rennard S., Dale D., Donohue J., Kanniess F., Magnussen H., Sutherland E., et al. (2015) CXCR2 antagonist Mk-7123-a phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am J Resp Crit Care Med 191: 1001-1011.
152. Rhee C., Kim J., Park C., Kim J., Kang J., Kim S., et al. (2011) Effect of imatinib on airway smooth muscle thickening in a murine model of chronic asthma. Int Arch Allergy Immunol 155: 243-251.
153. Richards D., Bareille P., Lindo E., Quinn D., Farrow S., (2010) Treatment with a peroxisomal proliferator activated receptor gamma agonist has a modest effect in the allergen challenge model in asthma: a randomised controlled trial. Respir Med 104: 668-674.
154. Saffar A., Ashdown H., Gounni A., (2011) The molecular mechanisms of glucocorticoids-mediated neutrophil survival. Curr Drug Targets 12: 556-562.
155. Samson K., Minoguchi K., Tanaka A., Oda N., Yokoe T., Yamamoto Y., et al. (2006) Inhibitory effects of fluvastatin on cytokine and chemokine production by peripheral blood mononuclear cells in patients with allergic asthma. Clin Exp Allergy 36: 475-482.
156. Schleich F., Chevremont A., Paulus V., Henket M., Manise M., Seidel L., et al. (2014) Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. Eur Respir J 44: 97-108.
157. Schleich F., Manise M., Sele J., Henket M., Seidel L., Louis R., (2013) Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation. BMC Pulm Med 13: 11.
158. Schögler A., Kopf B., Edwards M., Johnston S., Casaulta C., Kieninger E., et al. (2015) Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells. Eur Respir J 45: 428-439.
159. Seidel P., Alkhouri H., Lalor D., Burgess J., Armour C., Hughes J., (2012) Thiazolidinediones inhibit airway smooth muscle release of the chemokine CXCL10: in vitro comparison with current asthma therapies. Respir Res 13: 90-90.
160. Shaw D., Berry M., Hargadon B., Mckenna S., Shelley M., Green R., et al. (2007) Association between neutrophilic airway inflammation and airflow limitation in adults with asthma. Chest 132: 1871-1875.
161. Shaw D., Sousa A., Fowler S., Fleming L., Roberts G., Corfield J., et al. (2015) Clinical and inflammatory characteristics of the European U-Biopred Adult Severe Asthma Cohort. Eur Respir J 46: 1308-1321.
162. Shen N., Wang J., Zhao M., Pei F., He B., (2011) Anti-interleukin-17 antibodies attenuate airway inflammation in tobacco-smoke-exposed mice. Inhal Toxicol 23: 212-218.
163. Shum A., (2015) T cell types that take your breath away. Sci Trans Med 7: 301fs333-301fs333.
164. Simpson J., Gibson P., Yang I., Upham J., James A., Reynolds P., et al. (2013) Impaired macrophage phagocytosis in noneosinophilic asthma. Clin Exp Allergy 43: 29-35.
165. Simpson J., Gibson P., Yang I., Upham J., James A., Reynolds P., et al. (2014a) Altered sputum granzyme B and granzyme B/proteinase inhibitor-9 in patients with noneosinophilic asthma. Respirology 19: 280-287.
166. Simpson J., Grissell T., Douwes J., Scott R., Boyle M., Gibson P., (2007) Innate immune activation in neutrophilic asthma and bronchiectasis. Thorax 62: 211-218.
167. Simpson J., Guest M., Boggess M., Gibson P., (2015) Occupational exposures, smoking and airway inflammation in refractory asthma. BMC Pulm Med 14: 207.
168. Simpson J., Mcelduff P., Gibson P., (2010) Assessment and reproducibility of noneosinophilic asthma using induced sputum. Respiration 79: 147-151.
169. Simpson J., Phipps S., Baines K., Oreo K., Gunawardhana L., Gibson P., (2014b) Elevated expression of the NLRP3 inflammasome in neutrophilic asthma. Eur Respir J 43: 1067-1076.
170. Simpson J., Powell H., Boyle M., Scott R., Gibson P., (2008) Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med 177: 148-155.
171. Simpson J., Scott R., Boyle M., Gibson P., (2006) Inflammatory Subtypes in Asthma: Assessment and Identification Using Induced Sputum. Respirol 11: 54-61.
172. Simpson J.L., Milne D.G., Gibson P.G., (2009) Neutrophilic Asthma Has Different Radiographic Features to COPD and Smokers. Resp Med 103: 881-887.
173. Singh D., Petavy F., Macdonald A., Lazaar A., O'Connor B., (2010) The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Resp Res 11: 26.
174. Spahn J., Fost D., Covar R., Martin R., Brown E., Sj S., et al. (2001) Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study. Ann Allergy Asthma Immunol 87: 501-505.
175. Spears M., Donnelly I., Jolly L., Brannigan M., Ito K., McSharry C., et al. (2009a) Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study. Eur Respir J 33: 1010-1017.
176. Spears M., Donnelly I., Jolly L., Brannigan M., Ito K., McSharry C., et al. (2009b) Bronchodilatory effect of the PPAR-[gamma] agonist rosiglitazone in smokers with asthma. Clin Pharmacol Ther 86: 49-53.
177. Spears M., McSharry C., Thomson N.C., (2006) Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. Clin Exp Allergy 36: 1494-1504.
178. Stephen J., Delvecchio C., Spitale N., Giesler A., Radford K., Bilan P., et al. (2013) PPAR ligands decrease human airway smooth muscle cell migration and extracellular matrix synthesis. Eur Respir J 41: 425-432.
179. Suárez-Cuartín G., Crespo A., Mateus E., Torrejón M., Giner J., Belda A., et al. (2015) Variability in asthma inflammatory phenotype in induced sputum. Frequency and causes. Arch Bronconeumol 4. pii: S0300-2896(15)00110-6. doi: 10.1016/j.arbres.2015.03.007. [Epub ahead of print]
180. Sukkar M., Wood L., Tooze M., Simpson J., Mcdonald V., Gibson P., et al. (2012) Soluble rage is deficient in neutrophilic asthma and COPD. Eur Respir J 39: 721-729.
181. Thomson N., (2014) Novel therapies targeting eosinophilic inflammation in asthma. Clin Exp Allergy 44: 462-468.
182. Thomson N., Charron C., Chaudhuri R., Spears M., Ito K., McSharry C., (2015) Atorvastatin in combination with inhaled beclometasone modulates inflammatory sputum mediators in smokers with asthma. Pulm Pharmacol Ther 31: 1-8.
183. Thomson N., Chaudhuri R., Heaney L., Bucknall C., Niven R., Brightling C., et al. (2013) Clinical outcomes and inflammatory biomarkers in current smokers and exsmokers with severe asthma. J Allergy Clin Immunol 131: 1008-1016.
184. Thomson N., Chaudhuri R., Thomson N., Chaudhuri R., (2009) Asthma in smokers: challenges and opportunities. Curr Opin Pulm Med 15: 39-45.
185. To Y., Ito K., Kizawa Y., Failla M., Ito M., Kusama T., et al. (2010) Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 182: 897-904.
186. Trejo Bittar H., Yousem S., Wenzel S., (2015) Pathobiology of severe asthma. Annu Rev Pathol 10: 511-545.
187. Turner M., Hussack P., Sears M., Dolovich J., Hargreave F., (1995) Exacerbations of asthma without sputum eosinophilia. Thorax 50: 1057-1061.
188. Uddin M., Lau L., Seumois G., Vijayanand P., Staples K., Bagmane D., et al. (2013) EGF-induced bronchial epithelial cells drive neutrophil chemotactic and anti-apoptotic activity in asthma. PLoS ONE 8: e72502.
189. Uddin M., Nong G., Ward J., Seumois G., Prince L., Wilson S., et al. (2010) Prosurvival activity for airway neutrophils in severe asthma. Thorax 65:: 684-689.
190. Van Veen I., Ten Brinke A., Gauw S., Sterk P., Rabe K., Bel E., (2009) Consistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up study. J Allergy Clin Immunol 124: 615-617.e612.
191. Wagener A., De Nijs S., Lutter R., Sousa A., Weersink E., Bel E., et al. (2015) External validation of blood eosinophils, feno and serum periostin as surrogates for sputum eosinophils in asthma. Thorax 70: 115-120.
192. Wallace J., D'Silva L., Brannan J., Hargreave F., Kanaroglou P., Nair P., (2011) Association between proximity to major roads and sputum cell counts. Can Respir J 18: 13-18.
193. Wang F., He X., Baines K., Gunawardhana L., Simpson J., Li F., et al. (2011) Different inflammatory phenotypes in adults and children with acute asthma. Eur Respir J 38: 567-574.
194. Watz H., Mistry S., Lazaar A., Investigators. I., (2013) Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD. Pulm Pharmacol Ther 26: 588-595.
195. Wenzel S., Barnes P., Bleecker E., Bousquet J., Busse W., Dahlen S., et al. (2009) A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med 179: 549-558.
196. Wenzel S., Schwartz L., Langmack E., Al E., (1999) Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 160: 1001-1008.
197. Winkler D., Faia K., Dinitto J., Ali J., White K., Brophy E., et al. (2013) Pi3k-δ and Pi3k-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models. Chem Biol 20: 1364-1374.
198. Wood L., Baines K., Fu J., Scott H., Gibson P., (2012) The neutrophilic inflammatory phenotype is associated with systemic inflammation in asthma. Chest 142: 86-93.
199. Woodruff P., Modrek B., Choy D., Jia G., Abbas A., Ellwanger A., et al. (2009) T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med 180: 388-395.
200. Wu W., Chen H., Li Y., Wang S., Diao X., Liu K., (2014) Intranasal SIRNA targeting c-kit reduces airway inflammation in experimental allergic asthma. Int J Clin Exp Pathol 7: 5505-5514.
201. Wu W., Wang T., Dong J., Liao Z., Wen F., (2012) Silencing of c-kit with small interference RNA attenuates inflammation in a murine model of allergic asthma. Int J Mol Med 30: 63-68.
202. Xystrakis E., Kusumakar S., Boswell S., Peek E., Urry Z., Richards D., et al. (2006) Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest 116: 146-155.
203. Yeganeh B., Wiechec E., Ande S., Sharma P., Moghadam A., Post M., et al. (2014) Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacol Ther 143: 87-110.
204. Zeki A., Franzi L., Last J., Kenyon N., (2009) Simvastatin inhibits airway hyperreactivity: implications for the mevalonate pathway and beyond. Am J Respir Crit Care Med 180: 731-740.
205. Zhang X., Simpson J., Powell H., Yang I., Upham J., Reynolds P., et al. (2014) Full blood count parameters for the detection of asthma inflammatory phenotypes. Clin Exp Allergy 44: 1137-1145.
206. Zhang Y., Leung D., Goleva E., (2014) Anti-inflammatory and corticosteroid-enhancing actions of vitamin D in monocytes of patients with steroid-resistant and those with steroid-sensitive asthma. J Allergy Clin Immunol 133: 1744-1752.
207. Zhao Y., Huang Y., He J., Li C., Deng W., Ran X., et al. (2014) Rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, attenuates airway inflammation by inhibiting the proliferation of effector T cells in a murine model of neutrophilic asthma. Immunol Lett 157: 9-15.